In last trading session, Compass Therapeutics Inc (NASDAQ:CMPX) saw 1.16 million shares changing hands with its beta currently measuring 1.05. Company’s recent per share price level of $2.51 trading at -$0.02 or -0.79% at ring of the bell on the day assigns it a market valuation of $347.08M. That closing price of CMPX’s stock is at a discount of -62.55% from its 52-week high price of $4.08 and is indicating a premium of 69.72% from its 52-week low price of $0.76. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.75 million shares which gives us an average trading volume of 1.45 million if we extend that period to 3-months.
For Compass Therapeutics Inc (CMPX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.30. Splitting up the data highlights that, out of 2 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.11 in the current quarter.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Upright in the red during last session for losing -0.79%, in the last five days CMPX remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $2.51 price level, adding 10.04% to its value on the day. Compass Therapeutics Inc’s shares saw a change of 73.10% in year-to-date performance and have moved -9.39% in past 5-day. Compass Therapeutics Inc (NASDAQ:CMPX) showed a performance of -35.64% in past 30-days. Number of shares sold short was 3.7 million shares which calculate 3.05 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 49.8% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -99.2% in reaching the projected high whereas dropping to the targeted low would mean a loss of -99.2% for stock’s current value.
Compass Therapeutics Inc (CMPX) estimates and forecasts
This year revenue growth is estimated to rise 44.71% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -104.70% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -25.56% while estimates for its earnings growth in next 5 years are of 33.35%.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
Insiders are in possession of 18.08% of company’s total shares while institution are holding 70.94 percent of that, with stock having share float percentage of 86.59%. Investors also watch the number of corporate investors in a company very closely, which is 70.94% institutions for Compass Therapeutics Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at CMPX for having 22.36 million shares of worth $22.36 million. And as of 2024-06-30, it was holding 16.2534 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 11.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.0893 of outstanding shares, having a total worth of $11.13 million.
